GREENWOOD VILLAGE, Colo. and LOS ANGELES, July 26, 2022 /PRNewswire/ — ANANDA Scientific Inc., a analysis centered bio-pharmaceutical firm as we speak introduced the first affected person enrolled in the scientific trial evaluating Nantheia™ ATL5, an investigational drug utilizing cannabidiol (CBD) in ANANDA’s proprietary supply expertise as an Adjunctive Treatment for Opioid Use Disorder. (Clinical Trials.gov Identifier: NCT03787628)
This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences in addition to Molecular and Medicinal Pharmacology at the Semel Institute, Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D., Professor of Psychiatry and Biobehavioral Sciences at the Semel Institute, Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse (NIDA).
"The first patient enrolled in this study is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder," mentioned Dr. London. "Bridging psychiatry, pharmacology and neuroscience, we are looking to develop evidence-based treatments for addiction."
"We are excited to be moving this trial forward after completing all the preparatory work." mentioned Dr. De La Garza. "We hope this clinical trial will answer important questions about the potential of cannabidiol in the treatment of opioid addiction."
"We are delighted to have the first patient enrolled in this important trial of our investigational drug Nantheia™ ATL5. This clinical study is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need," mentioned Sohail R. Zaidi, ANANDA’s Chief Executive Officer (CEO). "We are impressed by the clinical competence and operational diligence of the clinical trial team at UCLA which makes them our partner of choice for future trials as we develop the clinical program"
This will likely be a randomized, double-blind, placebo managed, sequential, dose-ranging examine of Cannabidiol (CBD) (600, 1200 mg/day) as an adjunctive remedy to buprenorphine and naloxone in sufferers who’ve Opioid Use Disorder and are receiving residential behavioral remedy, together with cognitive behavioral remedy. The major endpoint will likely be security and tolerability of CBD in these sufferers, Secondary measures will embody cue-induced craving, reductions in spontaneous craving, opioid withdrawal, adverse affective states, and relapse, in addition to retention in remedy with buprenorphine and naloxone.
Nantheia™ ATL5 is an investigational drug that makes use of cannabidiol in ANANDA’s propriety Liquid Structure supply expertise. Pre-clinical and preliminary scientific research present that ANANDA’s Liquid Structure™ supply expertise (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100mg cannabidiol per softgel capsule.
ANANDA is a number one research-focused biopharmaceutical firm pioneering high-caliber scientific research evaluating therapeutic indications akin to PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The firm employs patented supply expertise to make cannabinoids and different plant derived compounds extremely bioavailable, water soluble, and shelf-life steady and focuses on producing efficient, premium high quality pharmaceutical merchandise. The firm is increasing its analysis base via a number of sponsored analysis agreements with universities to diversify its scientific portfolio. Consistent with its robust research-based information, the firm has a rising pipeline of nutraceutical over-the-counter merchandise. ANANDA has efficiently launched these merchandise in the US, Australia, and the UK, with enlargement into further markets akin to the EU, China, Africa, and different nations in Asia.
Contacts
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | [email protected]
Photo – https://mma.prnewswire.com/media/1864951/UCLA_Principle_Investigators.jpg
